Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
The New Zealand Medical Journal
|
December 7, 2011
Do pharmaceutical score cards give us the answers we seek?
Peter Moodie, Scott Metcalfe, Matthew Poynton
The New Zealand Medical Journal
|
November 1, 2005
PHARMAC responds on long-acting insulin analogues
Scott Metcalfe, Jackie Evans, Peter Moodie
The New Zealand Medical Journal
|
December 24, 2005
PHARMAC responds on treatments for pulmonary arterial hypertension
Scott Metcalfe, Dilky Rasiah, Sean Dougherty
Emotion, Space and Society
|
December 26, 2022
"Love is calling": Academic friendship and international research collaboration amid a global pandemic
Amy Scott Metcalfe, Gerardo L Blanco
The New Zealand Medical Journal
|
October 29, 2013
Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis
Scott Metcalfe, George Laking, Jason Arnold
The New Zealand Medical Journal
|
June 29, 2016
Child abuse in Australian camps-whose business, and who should speak out?
Ian Hassall, Scott Metcalfe, Alison Blaiklock
The New Zealand Medical Journal
|
March 3, 2012
PHARMAC has no cost-effectiveness threshold
Scott Metcalfe, Alexander Rodgers, Rachel Werner, et al.
The New Zealand Medical Journal
|
September 19, 2013
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis
Rachel Grocott, Scott Metcalfe, Paul Alexander, et al.
The New Zealand Medical Journal
|
December 24, 2005
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly
Scott Metcalfe, Steffan Crausaz, Peter Moodie, et al.
The American Journal of Medicine
|
May 26, 2007
Balancing the risks and benefits of celecoxib
Brent Caldwell, Richard Beasley, Mark Weatherall, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
The New Zealand Medical Journal
|
December 7, 2011
Do pharmaceutical score cards give us the answers we seek?
Peter Moodie, Scott Metcalfe, Matthew Poynton
The New Zealand Medical Journal
|
November 1, 2005
PHARMAC responds on long-acting insulin analogues
Scott Metcalfe, Jackie Evans, Peter Moodie
The New Zealand Medical Journal
|
December 24, 2005
PHARMAC responds on treatments for pulmonary arterial hypertension
Scott Metcalfe, Dilky Rasiah, Sean Dougherty
Emotion, Space and Society
|
December 26, 2022
"Love is calling": Academic friendship and international research collaboration amid a global pandemic
Amy Scott Metcalfe, Gerardo L Blanco
The New Zealand Medical Journal
|
October 29, 2013
Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis
Scott Metcalfe, George Laking, Jason Arnold
The New Zealand Medical Journal
|
June 29, 2016
Child abuse in Australian camps-whose business, and who should speak out?
Ian Hassall, Scott Metcalfe, Alison Blaiklock
The New Zealand Medical Journal
|
March 3, 2012
PHARMAC has no cost-effectiveness threshold
Scott Metcalfe, Alexander Rodgers, Rachel Werner, et al.
The New Zealand Medical Journal
|
September 19, 2013
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis
Rachel Grocott, Scott Metcalfe, Paul Alexander, et al.
The New Zealand Medical Journal
|
December 24, 2005
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly
Scott Metcalfe, Steffan Crausaz, Peter Moodie, et al.
The American Journal of Medicine
|
May 26, 2007
Balancing the risks and benefits of celecoxib
Brent Caldwell, Richard Beasley, Mark Weatherall, et al.
Page
of 7